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group in the southern U.S. Migration to interferon-
beta-1a from competitors was based on market-share
data for new and existing MS patients. Duration of
therapy was estimated by analyzing claims for current MS
therapies. Daily therapy cost was provided by the manu-
facturer, adjusted for migration from other therapies, and
multiplied by estimated volume to predict incremental
and total per-member, per-month (PMPM) impact.
Market-share estimates were used to develop a PMPM
forecast for the next two years. PMPM estimates were
calculated for preferred and non-preferred formulary tier
designs with and without prior authorization (PA). One-
way sensitivity analysis was performed to assess inﬂuence
of product pricing, duration of therapy, and other market
factors. RESULTS: Annual incremental PMPM change
was $0.047 for the third co-payment tier with PA sce-
nario. The incremental change was greatest for those 
aged 55 to 65 years ($0.056 PMPM) and did not vary
greatly by beneﬁt design. Duration of therapy has the
greatest impact on the PMPM estimate across beneﬁt
designs. CONCLUSIONS: Interferon-beta-1a will not
cause a signiﬁcant change in managed care pharmacy
budgets under a variety of formulary conditions, accord-
ing to this cross-sectional analysis of current care-seeking
behavior by MS patients. Economic impact may differ 
if interferon-beta-1-a expands MS patients’ treatment-
seeking behavior.
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OBJECTIVE: Schizophrenia is a chronic condition asso-
ciated with a signiﬁcant burden of disease and high health
care costs. The Schizophrenia Care and Assessment
Program (SCAP) is a naturalistic, observational study that
aims to collect information on a range of treatment out-
comes (clinical, functional and social) as well as detailed
information on health care service utilisation and associ-
ated costs. METHODS: The Australian arm of this study
involves 350 participants recruited from a large regional
mental health service in outer Melbourne. Participants are
assessed every six months. Health care resource data are
collected via a combination of electronic systems, includ-
ing a national medical and prescription claims database,
a state-based patient registry and a hospital pharmacy
information management system. RESULTS: The ﬁrst 18-
month longitudinal analysis of the complete SCAP cohort
reveals that the average total cost of health care services
and medications per patient during the 18 months was
AUD21,287 (€12,559). The most expensive component
of the total costs was inhospital treatment (71%), 
followed by outpatient services (17%) and medications
(12%). The average cost of medications dispensed to 
the subjects during the 18-month period was AUD2570
(€1516). Eighty percent of the subjects had medication
costs of less than AUD5000. In contrast, 2.3% of sub-
jects had costs greater than AUD10,000 (€5900) and
accounted for 10% of the total medication costs. CON-
CLUSIONS: While medications remain an important part
of the treatment strategy for people with schizophrenia,
they are only a small proportion of the overall cost 
of care. The most expensive component is inhospital
treatment.
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OBJECTIVE: To evaluate medication use patterns and
healthcare costs for individuals with schizophrenia
treated with haloperidol, olanzapine or risperidone in a
Medicaid program. METHODS: Medicaid recipients
who were diagnosed with schizophrenia (ICD-9 295.XX)
and began treatment with haloperidol (n = 302), olanza-
pine (n = 895), or risperidone (n = 479) between January
1997 and June 1997 were followed for 1 year. Me-
dical service and pharmacy claims one-year prior and
post-initiation were extracted and analyzed. Length of 
treatment, total and component healthcare costs were
compared using regression models controlling for demo-
graphic and clinical characteristics and previous service
and medication use. RESULTS: Compared to haloperidol
and risperidone users, patients using olanzapine stayed on
therapy signiﬁcantly longer (+69 days vs. haloperidol, p
< .0001; +29 days vs. risperidone, p < .0001). Olanzap-
ine patients had higher antipsychotic medication costs
(+$1269 vs. haloperidol, p < .0001; +$562 vs. risperi-
done, p < .0001) but lower psychiatric inpatient costs 
(-$1713 vs. haloperidol, p = .02; -$305 vs. risperidone,
p = 0.62). There were no signiﬁcant differences in total
healthcare costs (-$304 vs. haloperidol, p = .74 and -$49
vs. risperidone, p = .95). CONCLUSION: Longer treat-
ment duration, reductions in hospitalization costs and
similar total costs associated with olanzapine treatment
may be indicative of better patient outcomes.
